Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?
Cristina Adriana Popa
NephJC Internship 2026-2027

Introducing NephJC’s brand new editorial internship class of 2026-2027

NephJC Internship 2026-2027
Background
Cristina Adriana Popa
Making an IMPACT on BP: Why pills alone won't ...

This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.

Making an IMPACT on BP: Why pills alone won't win the war
Background
Cristina Adriana Popa
Is TRPC6 inhibition for FSGS a trick or a treat?

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.

Is TRPC6 inhibition for FSGS a trick or a treat?
Background
Cristina Adriana Popa
Why-dralazine?! Population risk of drug induced ...

This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?

Why-dralazine?! Population risk of drug induced vasculitis

Background

Making an IMPACT on BP: Why pills alone won't win the war

Making an IMPACT on BP: Why pills alone won't win the war

This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.

Is TRPC6 inhibition for FSGS a trick or a treat?

Is TRPC6 inhibition for FSGS a trick or a treat?

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.

Why-dralazine?! Population risk of drug induced vasculitis

Why-dralazine?! Population risk of drug induced vasculitis

This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?

Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia

Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia

This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?

,

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

,
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.